Year All2026202520242023202220212020 Jul 01, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30, 2026 Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Jun 25, 2026 Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Jun 02, 2026 Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Jun 01, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2026 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting May 14, 2026 Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights May 13, 2026 Candel Therapeutics to Present at Upcoming Investor Conferences May 04, 2026 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting May 01, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2026 Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Jun 02, 2026 Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
May 15, 2026 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
May 14, 2026 Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 04, 2026 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
